Clinical trials: Unspecified Adult Solid Tumor, Protocol Specific, completed
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Docetaxel in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American…
- Conditions
- Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00003565
- Testing
- docetaxel
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Unspecified Adult Solid Tumor, Protocol Specific
PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, docetaxel, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00459836
- Testing
- PR-104, docetaxel, gemcitabine hydrochloride
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 42 people
- Sponsor
- Proacta, Incorporated
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.
- Trial name
- NCT01898130
- Testing
- bevacizumab, quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Unspecified Adult Solid Tumor, Protocol Specific
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006464
- Testing
- 7-hydroxystaurosporine, cisplatin
- Where
- 4 sites in United States
- Sponsor
- City of Hope Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells and make the tumor more sensitive to…
- Trial name
- NCT00004864
- Testing
- GEM 231, docetaxel
- Where
- United States
- Sponsor
- Montefiore Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection on a weekly schedule in patients with advanced…
- Trial name
- NCT01028859
- Testing
- CKD-516 inj
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Unspecified Adult Solid Tumor, Protocol Specific
Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase I trial to study the effectiveness of sarcosinamide nitrosourea in treating patients who have metastatic or unresectable solid tumors.
- Trial name
- NCT00004079
- Testing
- SarCNU, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Small Intestine Cancer
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049400
- Testing
- BMS-247550
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- SWOG Cancer Research Network
Unspecified Adult Solid Tumor, Protocol Specific
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00004216
- Testing
- salmonella VNP20009, cefixime, ceftriaxone sodium
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Unspecified Adult Solid Tumor
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of giving pemetrexed disodium and sorafenib tosylate together in treating patients with advanced solid tumors.
- Trial name
- NCT01450384
- Testing
- sorafenib tosylate, pemetrexed disodium, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Virginia Commonwealth University
Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of L-778,123 in treating patients with recurrent or…
- Trial name
- NCT00003430
- Testing
- L-778,123
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study genetic testing and the effectiveness of irinotecan in treating patients who have solid tumors and lymphoma.
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00003970
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
S0916, MLN1202 in Treating Patients With Bone Metastases
RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01015560
- Testing
- anti-CCR2 monoclonal antibody MLN1202, polymorphism analysis, laboratory biomarker analysis
- Where
- 47 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Unspecified Adult Solid Tumor, Protocol Specific
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of lurtotecan liposome in treating patients who have…
- Trial name
- NCT00003891
- Testing
- lurtotecan liposome
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- NCIC Clinical Trials Group
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00401180
- Testing
- docetaxel, temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Cleveland Clinic
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Unspecified Adult Solid Tumor, Protocol Specific
Etoposide and Celecoxib in Patients With Advanced Cancer
RATIONALE: Etoposide and celecoxib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving more than 1 drug may be an effective treatment for advanced cancer.
- Trial name
- NCT00551005
- Testing
- celecoxib, etoposide, immunoenzyme technique
- Volunteers
- 58 people
- Sponsor
- City of Hope Medical Center